Keywords: Amgen, Prolia, Denosumab, ASCO, Osteoporosis, Cancer

More good news for Amgen as denosumab shows promise in cancer patients

Article | 7 June 2010

Print This

US biotechnology major Amgen received a further boost over the weekend, when it announced positive results at the prestigious annual ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in